Monitoring antimalarial drug resistance: Making the most of the tools at hand

Journal of Experimental Biology

Volumn 206, Issue 21, 2003, Pages 3745-3752

  Plowe, Christopher V ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Chloroquine; Dihydrofolate reductase; Dihydropteroate synthase; Drug resistance; PfCRT; Plasmodium falciparum; Sulfadoxine pyrimethamine

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; FOLIC ACID ANTAGONIST;

ANIMAL; DRUG MONITORING; DRUG RESISTANCE; GENETIC MARKER; GENETICS; GENOTYPE; HEALTH CARE POLICY; MALARIA FALCIPARUM; MALAWI; MUTATION; PARASITEMIA; PLASMODIUM FALCIPARUM; REVIEW;

ANIMALS; ANTIMALARIALS; CHLOROQUINE; DRUG MONITORING; DRUG RESISTANCE; FOLIC ACID ANTAGONISTS; GENETIC MARKERS; GENOTYPE; HEALTH POLICY; MALARIA, FALCIPARUM; MALAWI; MUTATION; PARASITEMIA; PLASMODIUM FALCIPARUM;

ANIMALIA; PLASMODIUM FALCIPARUM;

EID: 0242406973     PISSN: 00220949     EISSN: None     Source Type: Journal    
DOI: 10.1242/jeb.00658     Document Type: Review

References (60)

1. Adjuik, M., Agnamey, P., Babiker, A., Borrmann, S., Brasseur, P., Cisse, M., Cobelens, F., Diallo, S., Faucher, J. F., Garner, P. et al. (2002). Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 359, 1365-1372.
2. Bloland, P. B., Ettling, M. and Meek, S. (2000). Combination therapy for malaria in Africa: hype or hope? Bull. WHO 78, 1378-1388.
3. Bloland, P. B., Lackritz, E. M., Kazembe, P. N., Were, J. B., Steketee, R. and Campbell, C. C. (1993). Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J. Infect. Dis. 167, 932-937.
4. Brooks, D. R., Wang, P., Read, M., Watkins, W. M., Sims, P. F. and Hyde, J. E. (1994). Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem. 224, 397-405.
5. Cooper, R. A., Ferdig, M. T., Su, X. Z., Ursos, L. M., Mu, J., Nomura, T., Fujioka, H., Fidock, D. A., Roepe, P. D. and Wellems, T. E. (2002). Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. Mol. Pharmacol. 61, 35-42.
6. Cowman, A. F., Morry, M. J., Biggs, B. A., Cross, G. A. and Foote, S. J. (1988). Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 85, 9109-9113.
7. Curtis, J., Duraisingh, M. T. and Warhurst, D. C. (1998). In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment. J. Infect. Dis. 177, 1429-1433.
8. Diourte, Y., Djimde, A., Doumbo, O. K., Sagara, I., Coulibaly, A., Dicko, A., Diallo, M., Diakite, M., Cortese, J. F. and Plowe, C. V. (1999). Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. Am. J. Trop. Med. Hyg. 60, 475-478.
9. Djimde, A., Doumbo, O. K., Cortese, J. F., Kayentao, K., Doumbo, S., Diourte, Y., Dicko, A., Su, X. Z., Nomura, T., Fidock, D. A. et al. (2001a). A molecular marker for chloroquine-resistant falciparum malaria. New Engl. J. Med. 344, 257-263.
10. Djimde, A., Doumbo, O. K., Steketee, R. W. and Plowe, C. V. (2001b). Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet 358, 890-891.
11. Djimde, A. A., Doumbo, O. K., Traore, O., Guindo, A. B., Kayentao, K., Diourte, Y., Niare-Doumbo, S., Coulibaly, D., Kone, A. K., Cissoko, Y. et al. (in press). Clearance of drug-resistant parasites as a model for protective immunity in falciparum malaria. Am. J. Trop. Med. Hyg.
12. Doherty, J. F., Sadiq, A. D., Bayo, L., Alloueche, A., Olliaro, P., Milligan, P., von Seidlein, L. and Pinder, M. (1999). A randomized safety and tolerability trial of artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone for the treatment of uncomplicated malaria in Gambian children. Trans. R. Soc. Trop. Med. Hyg. 93, 543-546.
13. Dorsey, G., Njama, D., Kamya, M. R., Cattamanchi, A., Kyabayinze, D., Staedke, S. G., Gasasira, A. and Rosenthal, P. J. (2002). Sulfadoxine/ pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 360, 2031-2038.
14. Doumbo, O. K., Kayentao, K., Djimde, A., Cortese, J. F., Diourte, Y., Konare, A., Kublin, J. G. and Plowe, C. V. (2000). Rapid selection of plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis. J. Infect. Dis. 182, 993-996.
15. Enne, V. I., Livermore, D. M., Stephens, P. and Hall, L. M. (2001). Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 357, 1325-1328.
16. Fidock, D. A., Nomura, T., Cooper, R. A., Su, X., Talley, A. K. and Wellems, T. E. (2000a). Allelic modifications of the cg2 and cg1 genes do not alter the chloroquine response of drug-resistant plasmodium falciparum. Mol. Biochem. Parasitol. 110, 1-10.
17. Fidock, D. A., Nomura, T., Talley, A. K., Cooper, R. A., Dzekunov, S. M., Ferdig, M. T., Ursos, L. M., bir Singh, S. A., Naude, B., Deitsch, K. W. et al. (2000b). Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6, 861-871.
18. Foote, S. J. and Cowman, A. F. (1994). The mode of action and the mechanism of resistance to antimalarial drugs. Acta Trop. 56, 157-171.
19. Foote, S. J., Galatis, D. and Cowman, A. F. (1990). Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. USA 87, 3014-3017.
20. Greenberg, A. E., Ntumbanzondo, M., Ntula, N., Mawa, L., Howell, J. and Davachi, F. (1989). Hospital-based surveillance of malaria-related paediatric morbidity and mortality in Kinshasa, Zaire. Bull. WHO 67, 189-196.
21. Kublin, J. G., Cortese, J. F., Njunju, E. M., Mukadam, R. A. G., Wirima, J. J., Kazembe, P. N., Djimde, A. A., Kouriba, B., Taylor, T. E. and Plowe, C. V. (2003). Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J. Infect. Dis. 187, 1870-1875.
22. Kublin, J. G., Dzinjalamala, F. K., Kamwendo, D. D., Malkin, E. M., Cortese, J. F., Martino, L. M., Mukadam, R. A., Rogerson, S. J., Lescano, A. G., Molyneux, M. E. et al. (2002). Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 185, 380-388.
23. Levin, B. R., Perrot, V. and Walker, N. (2000). Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154, 985-997.
24. Mita, T., Kaneko, A., Lum, J. K., Bwijo, B., Takechi, N., Zungu, I. L., Tsukahara, T., Tanabe, K., Kobayakawa, T. and Bjorkman, A. (2003). Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am. J. Trop. Med. Hyg. 68, 413-415.
25. Mutabingwa, T., Nzila, A., Mberu, E., Nduati, E., Winstanley, P., Hills, E. and Watkins, W. (2001a). Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 358, 1218-1223.
26. Mutabingwa, T. K., Maxwell, C. A., Sia, I. G., Msuya, F. H., Mkongewa, S., Vannithone, S., Curtis, J. and Curtis, C. F. (2001b). A trial of proguanil-dapsone in comparison with sulfadoxine-pyrimethamine for the clearance of Plasmodium falciparum infections in Tanzania. Trans. R. Soc. Trop. Med. Hyg. 95, 433-438.
27. Nguyen-Dinh, P. and Payne, D. (1980). Pyrimethamine sensitivity in Plasmodium falciparum: determination in vitro by a modified 48-hour test. Bull. WHO 58, 909-912.
28. Nosten, F. and Brasseur, P. (2002). Combination therapy for malaria: the way forward? Drugs 62, 1315-1329.
29. Nosten, F., van Vugt, M., Price, R., Luxemburger, C., Thway, K. L., Brockman, A., McGready, R., ter Kuile, F., Looareesuwan, S. and White, N. J. (2000). Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356, 297-302.
30. Nzila, A. M., Mberu, E. K., Sulo, J., Dayo, H., Winstanley, P. A., Sibley, C. H. and Watkins, W. M. (2000a). Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob. Agents Chemother. 44, 991-996.
31. Nzila, A. M., Nduati, E., Mberu, E. K., Hopkins, S. C., Monks, S. A., Winstanley, P. A. and Watkins, W. M. (2000b). Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/ dapsone on Kenyan Plasmodium falciparum. J. Infect. Dis. 181, 2023-2028.
32. Peterson, D. S., Milhous, W. K. and Wellems, T. E. (1990). Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc. Natl. Acad. Sci. USA 87, 3018-3022.
33. Peterson, D. S., Walliker, D. and Wellems, T. E. (1988). Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. USA 85, 9114-9118.
34. Plowe, C. V., Cortese, J. F., Djimde, A., Nwanyanwu, O. C., Watkins, W. M., Winstanley, P. A., Estrada-Franco, J. G., Mollinedo, R. E., Avila, J. C., Cespedes, J. L. et al. (1997). Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J. Infect. Dis. 176, 1590-1596.
35. Plowe, C. V., Doumbo, O. K., Djimde, A., Kayentao, K., Diourte, Y., Doumbo, S. N., Coulibaly, D., Thera, M., Wellems, T. E. and Diallo, D. A. (2001). Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: parasitologic resistance versus therapeutic efficacy. Am. J. Trop. Med. Hyg. 64, 242-246.
36. Plowe, C. V., Kublin, J. G., Dzinjalamala, F. K., Kamwendo, D. S., Mukadam, R. A. G., Chimpeni, P., Molyneux, M. E. and Taylor, T. E. (in press). Sustained sulfadoxine-pyrimethamine efficacy for uncomplicated falciparum malaria in Malawi after ten years as first line therapy. Br. Med. J.
37. Price, R. N., Cassar, C., Brockman, A., Duraisingh, M., van Vugt, M., White, N. J., Nosten, F. and Krishna, S. (1999). The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob. Agents Chemother. 43, 2943-2949.
38. Price, R. N., Nosten, F., Luxemburger, C., ter Kuile, F. O., Paiphun, L., Chongsuphajaisiddhi, T. and White, N. J. (1996). Effects of artemisinin derivatives on malaria transmissibility. Lancet 347, 1654-1658.
39. Reed, M. B., Saliba, K. J., Caruana, S. R., Kirk, K. and Cowman, A. F. (2000). Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403, 906-909.
40. Robson, K. J., Walliker, D., Creasey, A., McBride, J. S., Beale, G. and Wilson, R. J. M. (1992). Cross contamination of Plasmodium cultures. Parasitol. Today 8, 38-39.
41. Sherman, D. R., Mdluli, K., Hickey, M. J., Arain, T. M., Morris, S. L., Barry, C. E., III and Stover, C. K. (1996). Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 212, 1641-1643.
42. Shretta, R., Omumbo, J., Rapuoda, B. and Snow, R. W. (2000). Using evidence to change antimalarial drug policy in Kenya. Trop. Med. Int. Health 5, 755-764.
43. Sidhu, A. B., Verdier-Pinard, D. and Fidock, D. A. (2002). Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298, 210-213.
44. Sulo, J., Chimpeni, P., Hatcher, J., Kublin, J. G., Plowe, C. V., Molyneux, M. E., Marsh, K., Taylor, T. E., Watkins, W. M. and Winstanley, P. A. (2002). Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet 360, 1136-1143.
45. Trape, J. F., Pison, G., Preziosi, M. P., Enel, C., Dulou, A. D., Delaunay, V., Samb, B., Lagarde, E., Molez, J. F. and Simondon, F. (1998). Impact of chloroquine resistance on malaria mortality. C. R. Acad. Sci. III 321, 689-697.
46. Triglia, T. and Cowman, A. F. (1994). Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 91, 7149-7153.
47. Triglia, T., Menting, J. G. T., Wilson, C. and Cowman, A. F. (1997). Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 94, 13944-13949.
48. van Hensbroek, M. B., Morris-Jones, S., Meisner, S., Jaffar, S., Bayo, L., Dackour, R., Phillips, C. and Greenwood, B. M. (1995). Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 89, 672-676.
49. von Seidlein, L., Milligan, P., Pinder, M., Bojang, K., Anyalebechi, C., Gosling, R., Coleman, R., Ude, J. I., Sadiq, A., Duraisingh, M. et al. (2000). Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet 355, 352-357.
50. Wang, P., Lee, C.-S., Bayoumi, R., Djimde, A., Doumbo, O., Swedberg, G., Dao, L. D., Mshinda, H., Tanner, M., Watkins, W. M. et al. (1997a). Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol. Biochem. Parasitol. 89, 161-177.
51. Wang, P., Read, M., Sims, P. F. and Hyde, J. E. (1997b). Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol. Microbiol. 23, 979-986.
52. Watkins, W. M., Mberu, E. K., Nevill, C. G., Ward, S. A., Breckenridge, A. M. and Koech, D. K. (1990). Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans. R. Soc. Trop. Med. Hyg. 84, 492-495.
53. Wellems, T. E. and Plowe, C. V. (2001). Chloroquine-resistant malaria. J. Infect. Dis. 184, 770-776.
54. White, N. J., Nosten, F., Looareesuwan, S., Watkins, W. M., Marsh, K., Snow, R. W., Kokwaro, G., Ouma, J., Hien, T. T., Molyneux, M. E. et al. (1999). Averting a malaria disaster. Lancet 353, 1965-1967.
55. World Health Organization (1973). Chemotherapy of Malaria and Resistance to Antimalarials. 529. WHO Technical Report Series. Geneva: World Health Organization.
56. World Health Organization (1996). Assessment of Therapeutic Efficacy of Antimalarial Drugs For Uncomplicated Falciparum Malaria in Areas With Intense Transmission. Geneva: Division of Control of Tropical Diseases, World Health Organization.
57. World Health Organization (2002). Monitoring Antimalarial Drug Resistance. WHO/CDS/CSR/EPH/2002.17 (ed. P. B. Bloland, U. D'Alessandro, P. Ringwald and W. M. Watkins). Geneva: World Health Organization.
58. Winstanley, P., Watkins, W., Muhia, D., Szwandt, S., Amukoye, E. and Marsh, K. (1997). Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range. Trans. R. Soc. Trop. Med. Hyg. 91, 322-327.
59. Winstanley, P. A. (2000). Chemotherapy for falciparum malaria: the armoury, the problems and the prospects. Parasitol. Today 16, 146-153.
60. Zolg, J. W., Plitt, J. R., Chen, G. X. and Palmer, S. (1989). Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol. Biochem. Parasitol. 36, 253-262.